Seredigm is focused on developing novel drugs that protect against tissue damage in a variety of acute or chronic medical conditions. Tissue damage plays a critical role in the pathogenesis of diverse life-threatening conditions, including a variety of acute cardiac indications and chronic diseases such as multiple sclerosis and asthma. According to the American Heart Association, more than 1 million Americans will have an acute cardiac event this year.  By protecting against life-threatening tissue damage, Seredigm’s products may have the potential to make a considerable difference in the lives of patients, and with this prospect comes a significant commercial opportunity.

Portfolio Home